drugset / Trial / NCT01631474
A Phase 2 Dose Escalating Study to Evaluate the Safety and Efficacy of CB-03-01 Cream in Subjects With Facial Acne Vulgaris
RandomizedParallel-groupDouble-blindTreatment
Summary
CB-03-01 is being developed for the topical treatment of acne vulgaris, an androgen-dependent skin disorder. The purpose of this study is to compare the safety and efficacy of multiple concentrations of CB-03-01 to vehicle in the treatment of acne vulgaris.
Timeline
- Start
- 2012-06
- Primary completion
- 2014-02
- Completion
- 2014-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Clascoterone | Small molecule | 0.1 % | Topical |
| Subject | Clascoterone | Small molecule | 0.5 % | Topical |
| Subject | Clascoterone | Small molecule | 1 % | Topical |